clinical trial · NCT07626437
Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common Cold and Flu in Adults
Brainfarma Industria Química e Farmacêutica S/A·phase3·recruiting·n = 620
Common Cold/FluNasal CongestionNasal Obstructiondipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mgdipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mgPlacebo
brief summary
Phase III clinical trial to evaluate the efficacy and safety of a fixed-dose combination of 1000 mg dipyrone monohydrate + 60 mg caffeine + 4 mg chlorpheniramine maleate in improving symptoms of the common cold and flu in adults.
started
May 8, 2026
primary completion
Jun 28, 2027
completion
Jun 30, 2027
last updated
Jun 16, 2026
official title
A Phase III, Multicenter, Double-blind, Randomized, Parallel-group Non-inferiority Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate Compared to Benegrip® in Improving Symptoms of the Common Cold and Flu in Adult Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol